CHEMICAL & MINING CO OF CHILE INC (SQM): what the price assumes

In the published model solve dated 2026-Q2, anchored at $70.05, CHEMICAL & MINING CO OF CHILE INC (SQM) is priced for +24.2% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-24.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/SQM

Headline

FieldValue
TickerSQM
CompanyCHEMICAL & MINING CO OF CHILE INC
Sector / IndustryBasic Materials
Current price$70.05/sh
CompositionSpecialty plant nutrients 21% / Iodine and its derivatives 23% / Lithium and its derivatives 50% / Industrial chemicals 2% / Potassium 3% / Other products and services 1%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)8.2%
Operating margin today23.5%
Margin compression (value-band)-15.3pp
Implied growth24.2%
Multiple paid23x operating income

The operating-margin figure is value-band context at year 9: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 9.8% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.3pp.

How unusual the bet is: within-range

ReferenceValue
vs own history-0.16σ
sustained it ~5 years at this level35%
implied end-window share0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset2.25x5expensive
Earnings1.28x3expensive
Relative1.61x2expensive
Growth0.90x3justifies

Families that justify the price: Growth Families that call it expensive: Asset, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.3%); the inversion above states its own rate.

Per-Model Detail (n=13)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$32.082.18xyesFCF base $0.3B, growth 25% (input: historical growth), terminal g 4.0%, WACC 8.3%, 5yr projection
DCF Exit MultipleGrowth$78.170.90xyesExit EV/EBITDA: 11.1x / 16.1x / 21.1x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelativenoP/E 18.48x (blended: static sector reference 14x + trailing (TTM) 29x), scenarios: 13.9x / 18.5x / 22.2x (bear / base = reference held flat / bull), EV/EBITDA 10.44x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$26.182.68xyesBV/sh $18.20, ROE (TTM) 13.3%, ke 9.3%
Two-Stage Excess ReturnAsset$31.132.25xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$101.630.69xyesRev $4.5B, growth 30% (input: historical growth; tapered), Terminal P/S: 3.3x / 4.4x / 5.3x (bear / base = today's held flat / bull, cap 6x)
Peter Lynch Fair ValueRelative$28.782.43xyesEPS $2.40, growth 2% (input: historical EPS growth), PEG=16.90 (Overvalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$54.731.28xyesNormalized EBIT (5y avg op income, one-time charges added back) $2.13B × (1−29%) / WACC 8.3% → EPV (no growth)
Residual IncomeAsset$32.192.18xyesBV $18.20 + 5yr PV of (ROE (TTM) 13.3% − Kₑ 9.3%) × BV; BV grows 8.7%/yr
Graham NumberAsset$31.342.24xyes√(22.5 × EPS $2.40 × BVPS $18.20) — Graham's conservative floor
EV/EBITDA RelativeRelativenoEBITDA $1.41B × sector EV/EBITDA 8.0x
FCF YieldEarnings$2.0134.85xyesFCF $302.9M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarnings$77.390.91xyesEPS $2.40 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$21.093.32xyesBV $18.20 × (ROIC 9.6% / WACC 8.3%)
P/Sales SectorRelativenoRevenue $4.53B × sector P/S 1.5x
PEG Fair ValueRelative$89.950.78xyesEPS $2.40 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$25.932.70xyesEPS $2.40 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
F-118operatingenterprise4528.8B reported-currencywithheldunresolved no unit value
F-119operatingenterprise7467.5B reported-currencywithheldunresolved no unit value

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

FieldValue
Net debt$4.7b
Net debt / NOPAT (after-tax)6.24x
Net debt / operating income (pre-tax)4.43x
Interest coverage5.4x
Burning cashno

Bullet Takeaways

Bull Case

Full capacity is a dull phrase until you watch what it does to an income statement. Every ton the company could make in the first quarter of 2026 found a buyer, about 69,000 metric tons of lithium carbonate equivalent, roughly a quarter more than the same period a year earlier. Revenue reached US$1,760.1 million, up 69.8%, and net income came to US$364.7 million, or US$1.28 a share, against US$0.48 a year before.

Lithium is the engine and it is running hot. Lithium and derivatives brought in US$1,185.5 million in the quarter, up 135.7% year on year, into a market management describes as tightly balanced. The demand mix has quietly changed underneath that number. Battery energy storage now accounts for something close to 30% of total lithium demand, which means the commodity is no longer a pure derivative of how many electric cars get sold in a given year.

Underneath sits the reason this producer keeps landing on the right side of the cost curve. The Salar de Atacama is brine, not hard rock. The lithium concentrates by evaporation in one of the driest places on earth, and the desert supplies that energy at no charge. What such an asset usually lacks is not ore but permission, and the December 2025 partnership with Codelco settled that: production rights in the salar now run to 2060, with an overall quota increase of 300,000 metric tons of lithium carbonate equivalent through the end of 2030. Three and a half decades of licensed access is a real asset. It was bought by handing the state a controlling stake.

The second business gets almost no attention and deserves some. This is the largest iodine producer in the world, selling into X-ray contrast media and disinfectants rather than batteries, and iodine revenue rose 8.2% to US$275.9 million in the quarter on both stronger volumes and firmer pricing, with particular strength across Asian markets. Specialty plant nutrition is a third leg, where management raised full-year volume guidance to roughly 10% growth after reduced Chinese potassium nitrate exports opened a supply gap. Neither line takes its direction from lithium.

The balance sheet supports the position rather than straining it. At the close of March the company held US$3,867 million in cash and short-term investments against US$5,208 million of total debt, with shareholders' equity of US$8,216 million. That is a producer with room to fund its own expansion through a downturn, which in this industry is the difference between buying assets and selling them. The dividend policy remains half of the prior year's net income, and management has said the board will revisit an interim special distribution as the year develops.

The bull case does not require heroics from here. It requires the lithium market to stay roughly where it is while contracted volumes grow about 15% this year, iodine holds its pricing, and specialty nutrition keeps taking share from displaced Chinese exports.

Bear Case

Strip the lithium price out of the last two quarters and the growth story gets much quieter.

Today's quote requires operating profit to compound at about 24.6% a year. What the company actually delivered in the most recent full year was revenue growth of 1.0%, to US$4,576.2 million, and that followed a year in which it lost money outright. The gap between those two facts is the entire bear case, and it has a specific mechanism.

The recovery was a price event, not an operating one. Realized lithium prices averaged about US$18 per kilogram in the first quarter against roughly US$10 in the fourth quarter of 2025. Volumes rose about 25%; revenue rose 69.8%. Almost everything above the volume line came from the market rather than the mine, and the market is the one input management explicitly declined to forecast past the current quarter.

Every competitor is drinking from the same well. Albemarle sold 53,000 metric tons of lithium carbonate equivalent in its own first quarter at an average realized price near US$17 per kilogram, lifted adjusted profitability by 148%, and used the proceeds to retire US$1.3 billion of borrowings. When an entire industry turns profitable at once, in a commodity with no switching cost and no brand, the reliable sequel is supply. That is the cycle doing what cycles do, and a company whose trailing year included an outright loss is not positioned to argue it has been repealed.

There is also a question about what a buyer actually owns. Since December 27, 2025 the Salar de Atacama operation has been held inside Nova Andino Litio, in which Codelco holds 50% plus one share. The venture is consolidated and managed from here only until 2031, at which point the board expands to seven members, Codelco appoints the chair, decisions move to simple majority, and control passes. The economics survive that handover. The decisions do not.

Chile takes a substantial cut along the way, and takes it early. In the first quarter alone the venture contributed more than US$530 million to the Chilean state through CORFO payments, taxes and local government transfers, and the mining royalty currently runs between 11% and 12% of lithium profitability. That is a claim on the good years specifically, which is the opposite of the profile a cyclical wants.

The next resource project is a long way off. Salar Futuro expects to file its environmental study before the end of the third quarter of 2026, with final approval anticipated during 2029 and investment starting in 2030. A permitting calendar that runs to the end of the decade is not the profile of a business that grows into a 24.6% requirement under its own power. It is one that needs the commodity to do the work.

The methods that refuse to extrapolate say the same thing more bluntly. The price sits about 2.25 times above where the book value methods land, and about 2.33 times above where peer multiples land. The projection-based methods are alone in reaching today's quote, and they arrive there by holding the current trading multiple flat through the whole forecast. That assumption is the argument, not evidence for it.

Valuation

Half of revenue is lithium, and lithium is where the bet lives. The rest, iodine at roughly a fifth and specialty plant nutrients at about the same, behaves like a different company attached to the same balance sheet.

What today's quote requires is specific: operating profit compounding at about 24.6% a year. Against a business that earns about 23.5% operating margins on its trailing results, that is not a demand for a better company. It is a demand for a much bigger one, at current economics, quickly.

The methods used to triangulate disagree sharply about whether that is available. The price sits about 2.25 times above where the book value methods land, and about 2.33 times above where peer multiples land. Earnings power sits closer, with the price about 1.28 times above where those methods reach. The projection-based lenses are the exception, and the one stretching furthest assumes the current trading multiple stays exactly where it is for the length of the forecast. That spread is the premium, and it has a plain reading: the static frames price a cyclical chemicals producer on what it has demonstrated, while the price is paying for a commodity recovery to persist and compound. Nothing in the static frames can express a lithium price, which is exactly why they land where they do.

The balance sheet is materially stronger than a quick read suggests, and it matters here because it decides who survives the next trough. At the end of March the company held US$3,867 million in cash and short-term investments against US$5,208 million of total debt, leaving net borrowings near US$1.3 billion against US$8,216 million of shareholders' equity. Interest was covered many times over by first-quarter operating profit. This is not a company whose downside is solvency; its downside is duration, the number of quarters it would spend earning very little if the commodity turned.

One structural item belongs in any read of the price. The salar that supplies the lithium is now held in a venture Codelco controls on paper and will control in practice from 2031. A buyer today is underwriting operating control that runs to 2031, then a long partnership in which someone else sets the agenda through 2060. The quota is secure. The steering wheel is on a timer.

Catalysts

The next scheduled information event is second-quarter earnings on August 18, 2026. Management has already said it expects realized lithium prices in the second quarter to come in above the first quarter's level, while declining to project beyond that, so the print carries both a near-certain positive and an open question about the second half.

Guidance was raised across two of the three main lines when first-quarter results landed. Full-year lithium sales volumes are now expected to grow roughly 15% against 2025, with Salar de Atacama volumes alone expected to exceed 270,000 metric tons; specialty plant nutrition volumes were lifted to approximately 10% growth; iodine volumes are guided flat to slightly higher. Those are volume commitments, which makes the second-quarter revenue line largely a question of price.

Two project decisions sit inside the next few months. The Mount Holland expansion review is scheduled for early in the third quarter of 2026, and the Salar Futuro environmental study is expected to be filed before the third quarter closes, with final approval anticipated during 2029 and investment beginning in 2030. Neither changes near-term output; both set the shape of the next decade.

On capital return, the standing policy distributes half of the prior year's net income, and management said the board has taken no decision on an interim special dividend but will reassess as the year progresses. A strong second quarter is the most likely trigger for that conversation.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Codelco-SQM joint venture completion, December 27, 2025 · SQM Q1 2026 earnings call · SQM Q1 2026 earnings release · Codelco-SQM joint venture, closed December 27, 2025 · SQM Q1 2026 earnings release and earnings call · SQM Q1 2026 balance sheet · SQM FY2025 results, February 28, 2026 · Albemarle Q1 2026 results · Codelco-SQM joint venture completion · SQM FY2025 Form 20-F · Codelco-SQM joint venture, December 27, 2025 · SQM investor calendar

View the full interactive SQM report on boothcheck